Case report: Heart Mate III for systemic right ventricular support in a patient with hypoplastic left heart syndrome

Hanuna, Maja; Ohain, Jelena Pabst von; Haas, Nikolaus A.; Mueller, Christoph; Dalla‐Pozza, Robert; Fischer, Marcus; Born, F.; Kamla, Christine; Jakob, André; Hagl, Christian; Hörer, Jürgen; Michel, Sebastian

doi:10.3389/fcvm.2022.1070314

Cited by 1 publication

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our current series of 82 children supported with pulsatile VAD, only 5 were supported after "Stage 1" palliation with parallel pulmonary and systemic circulations. 18 but also has been reported with the use of a subpulmonary assist device in failing Fontan patients with a preserved ejection fraction of the systemic ventricle. [19][20][21][22] In our current series of 82 children supported with pulsatile VAD, only 6 were supported with Fontan circulation.…”

Section: Commentmentioning

confidence: 92%

“…In our current series of 82 children supported with pulsatile VAD, only 2 were supported with “Stage 2 circulation,” or “Glenn physiology.” VAD support after “Stage 3,” in other words, VAD support in patients with Fontan circulation, is possible with both paracorporeal devices and intracorporeal implantable durable devices. Such support is not only most common in patients with systemic ventricular dysfunction and use of systemic ventricular support 18 but also has been reported with the use of a subpulmonary assist device in failing Fontan patients with a preserved ejection fraction of the systemic ventricle. 19–22 In our current series of 82 children supported with pulsatile VAD, only 6 were supported with Fontan circulation.…”

Section: Commentmentioning

confidence: 98%

See 1 more Smart Citation

Outcomes of Children Supported With Pulsatile Paracorporeal Ventricular Assist Device: Congenital Versus Acquired Heart Disease

Bleiweis,

Philip,

Stukov

et al. 2023

World J Pediatr Congenit Heart Surg

View full text Add to dashboard Cite

Background We reviewed the outcomes of 82 consecutive pediatric patients (less than 18 years of age) supported with the Berlin Heart ventricular assist device (VAD), comparing those with congenital heart disease (CHD; n = 44) with those with acquired heart disease (AHD; n = 37). Methods The primary outcome was mortality after VAD insertion. Kaplan-Meier methods and log-rank tests were used to assess group differences in long-term survival. Results Forty-four CHD patients were supported (age: median = 65 days, range = 4 days-13.3 years; weight [kg]: median = 4, range = 2.4-42.3). Ten biventricular CHD patients were supported with eight biventricular assist devices (BiVADs), one left ventricular assist device (LVAD) only, and one LVAD converted to BiVAD, while 34 univentricular CHD patients were supported with single ventricle-ventricular assist devices (sVADs). In CHD patients, duration of VAD support was [days]: median = 134, range = 4-554. Of 44 CHD patients, 28 underwent heart transplantation, 15 died on VAD, and one was still on VAD. Thirty-seven AHD patients were supported (age: median = 1.9 years, range = 27 days-17.7 years; weight [kg]: median = 11, range = 3.1-112), including 34 BiVAD and 3 LVAD. In AHD patients, duration of VAD support was [days]: median = 97, range = 4-315. Of 37 AHD patients, 28 underwent transplantation, three died on VAD, five weaned off VAD (one of whom underwent heart transplantation 334 days after weaning), and one was still on VAD. One-year survival after VAD insertion was 59.9% (95% CI = 46.7%-76.7%) in CHD and 88.6% (95% CI = 78.8%-99.8%) in AHD, P = .0004. Five-year survival after VAD insertion was 55.4% (95% CI = 40.8%-75.2%) in CHD and 85.3% (95% CI = 74.0%-98.2%) in AHD, P = .002. Conclusions Pulsatile VAD facilitates bridge-to-transplantation in neonates, infants, and children with CHD; however, survival after VAD insertion is worse in patients with CHD than in patients with AHD.

show abstract